Risk of developing neuroblastoma influenced by maternal stressful life events during pregnancy and congenital pathologies
Pediatric Blood & Cancer · 2025
DOI: 10.1002/pbc.31402 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Nuria Benavent und 9 weiteren Autor:innen. Beteiligte Einrichtung: Pathology Department, Medical School, University of Valencia, Valencia, Spain. Hauptthemen laut MEDLINE: Neuroblastoma, Stress, Psychological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ERDF (European Regional Development Fund), Fundación Neuroblastoma, ISCIII (FIS).
Abstract (Originalsprache)
Objective
A retrospective multicenter study to investigate the potential association between descriptive information related to pregnancy history and perinatal features and the risk of neuroblastoma (NB) in children. Study design Data from 56 mothers during 105 pregnancies (56 cases of NB, 49 control siblings) were collected through face‐to‐face or telephone interviews with mothers of children diagnosed with NB, along with information extracted from Health System databases. Descriptive information related to (a) pregnancy history as maternal stressful life events with perceived distress during pregnancy, weight gain, alcohol and tobacco consumption, mode of delivery and gestational age; and (b) perinatal features as congenital pathologies, weight at birth and type of feeding were examined to identify potential risk factors for NB.
Results
Stressful life events during pregnancy and certain congenital pathologies were independently associated with NB risk. No significant associations were found between other features. Breastfeeding rates were similar between cases and controls.
Conclusion
Our results underscore the importance of providing support and care to pregnant women to reduce potential stressors. Further research is needed to better understand the influence of dysbiosis and mitochondrial‐nuclear communication impairment as underlying mechanisms of maternal stress during pregnancy and presence of congenital pathologies in order to confirm them as potential risk factors for NB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pathology Department, Medical School, University of Valencia, Valencia, Spain.
- INCLIVA Biomedical Research Institute, Valencia, Spain.
- Pediatric Oncology Unit, Hospital Universitari i Politècnic La Fe, Valencia, Spain.
- Pediatric Oncology Unit, Vall d'Hebron University Hospital, Barcelona, Spain.
- Pediatric Oncology Unit, Hospital Clínico Universitario de Valencia, Valencia, Spain.
- Pediatric Oncology Unit, Hospital Universitario Son Espases, Palma de Mallorca, Spain.
ORCID-Profile: Nuria Benavent, Lucas Moreno, Juan Antonio Carbonell-Asins
Förderung
- ERDF (European Regional Development Fund)
- Fundación Neuroblastoma
- ISCIII (FIS)
- CIBERONC
Zitieren
APA
Benavent, N., Cañete, A., Moreno, L., Gros, L., Verdú-Amorós, J., Salinas, J. A., Navarro, S., Álvaro, T., Carbonell-Asins, J. A., & Noguera, R. (2025). Risk of developing neuroblastoma influenced by maternal stressful life events during pregnancy and congenital pathologies. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31402
Vancouver
Benavent N, Cañete A, Moreno L, Gros L, Verdú-Amorós J, Salinas JA, et al. Risk of developing neuroblastoma influenced by maternal stressful life events during pregnancy and congenital pathologies. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31402
BibTeX
@article{Benavent2025,
author = {Benavent, Nuria and Cañete, Adela and Moreno, Lucas and Gros, Luis and Verdú-Amorós, Jaime and Salinas, Jose Antonio and Navarro, Samuel and Álvaro, Tomas and Carbonell-Asins, Juan Antonio and Noguera, Rosa},
title = {Risk of developing neuroblastoma influenced by maternal stressful life events during pregnancy and congenital pathologies},
journal = {Pediatric Blood & Cancer},
year = {2025},
doi = {10.1002/pbc.31402}
}
EUVIMED